Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 81Neoplasms 64Colorectal Neoplasms 43Prostatic Neoplasms 41Carcinoma, Non-Small-Cell Lung 36Lung Neoplasms 31Leukemia, Myeloid, Acute 24Multiple Myeloma 23Head and Neck Neoplasms 23Melanoma 16Squamous Cell Carcinoma of Head and Neck 15Recurrence 15Pancreatic Neoplasms 15Neoplasm Metastasis 15Stomach Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Ovarian Neoplasms 14Carcinoma, Hepatocellular 14Lymphoma, Non-Hodgkin 13Colonic Neoplasms 11Uterine Cervical Neoplasms 10Rectal Neoplasms 10Lymphoma 10Esophageal Neoplasms 10Carcinoma, Renal Cell 10Brain Neoplasms 10Motor Activity 9Kidney Neoplasms 9Myelodysplastic Syndromes 8Lymphoma, Large B-Cell, Diffuse 8

Interventions

Panzyga 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Agammaglobulinemia × 30 days × Clear all
NCT04502030 2026-06-04

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Octapharma

Phase 3 Completed
247 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡